Frequency of No-Reflow Phenomenon in Patients Treated with Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
DOI:
https://doi.org/10.61919/jhrr.v4i1.573Keywords:
No-reflow phenomenon, ST-segment elevation myocardial infarction, Percutaneous coronary intervention, Risk factors, Scoring system, Logistic regression, Coronary angiography, Cardiology interventional procedures, Clinical predictors, Myocardial reperfusion injuryAbstract
Background: The no-reflow phenomenon is a critical complication following percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI), which can significantly affect morbidity and mortality. Despite advancements in interventional cardiology, no-reflow remains a challenge, with various factors contributing to its occurrence.
Objective: This study aims to identify independent risk factors for the no-reflow phenomenon in STEMI patients undergoing direct PCI and to develop a practical scoring system for predicting the likelihood of its occurrence.
Methods: In a retrospective cohort analysis, 1,345 patients who underwent direct PCI at a single center were evaluated. Baseline characteristics, clinical manifestations, and angiographic findings were meticulously recorded. Multivariate logistic regression was employed to ascertain independent predictors for no-reflow. The derived scoring system was based on statistically significant variables, including age, collateral circulation, thrombus burden, lesion diameter, and ACEI/ARB therapy.
Results: The mean age of the development cohort (n=1011) was 61.2±11.2 years, with the validation cohort (n=334) averaging 62.1±10.8 years. No-reflow was present in 80.1% of the development group with TIMI blood flow grade 1. Independent predictors of no-reflow included age ≥55 years (OR 2.100, p=0.001), collateral circulation <grade 2 (OR 2.907, p=0.002), thrombus burden ≥4 points (OR 1.920, p<0.001), and lack of ACEI/ARB therapy (OR 1.678, p=0.017). The scoring system demonstrated a sensitivity of 42.0% and a specificity of 78.4%, with PPV and NPV of 45.8% and 78.5%, respectively.
Conclusion: The study identified several key predictors for no-reflow and established a scoring system that may aid clinicians in the early identification of patients at risk for no-reflow post-PCI. This scoring system, given its simplicity and reliance on readily available clinical data, has the potential to be incorporated into routine clinical practice, subject to validation in future prospective studies.
Downloads
References
Okwuosa IS, Lewsey SC, Adesiyun T, et al. Worldwide disparities in cardiovascular disease: challenges and solutions. Int J Cardiol. 2016;202:433-40.
Li H, Ge J. Cardiovascular diseases in China: current status and future perspectives. Int J Cardiol Heart Vasc. 2015;6:25-31.
Li J, Li X, Wang Q, et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. Lancet. 2015;385:441-51.
De Luca G, Suryapranata H, Marino P. Reperfusion strategies in acute ST-elevation myocardial infarction: an overview of current status. Prog Cardiovasc Dis. 2008;50:352-82.
Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54:281-92.
Gupta S, Gupta MM. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart J. 2016;68:539-51.
Jaffe R, Charron T, Puley G, et al. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation. 2008;117:3152-6.
Harrison RW, Aggarwal A, Ou FS, et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol. 2013;111:178-84.
Rentrop KP, Cohen M, Blanke H, et al. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol. 1985;5:587-92.
Ndrepepa G, Mehilli J, Schulz S, et al. Prognostic significance of epicardial blood flow before and after percutaneous coronary intervention in patients with acute coronary syndromes. J Am Coll Cardiol. 2008;52:512-7.
Mehta RH, Harjai KJ, Boura J, et al. Prognostic significance of transient no-reflow during primary percutaneous coronary intervention for ST elevation acute myocardial infarction. Am J Cardiol. 2003;92:1445-7.
Yip HK, Chen MC, Chang HW, et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest. 2002;122:1322-32.
Tomaszuk-Kazberuk A, Sobkowicz B, Kaminski K, et al. Myocardial perfusion assessed by contrast echocardiography correlates with angiographic perfusion parameters in patients with a first acute myocardial infarction successfully treated with angioplasty. Can J Cardiol. 2008;24:633-9.
Horszczaruk GJ, Kwasiborski P, Rdzanek A, et al. TIMI myocardial perfusion grade and ST-segment resolution in the assessment of coronary reperfusion after primary angioplasty. Kardiol Pol. 2014;72:27-33.
Zhou H, He XY, Zhuang SW, et al. Clinical and procedural predictors of no-reflow in patients with acute myocardial infarction after primary percutaneous coronary intervention. World J Emerg Med. 2014;5:96-102.
Kirma C, Izgi A, Dundar C, et al. Clinical and procedural predictors of no-reflow phenomenon after primary percutaneous coronary interventions: experience at a single center. Circ J. 2008;72:716-21.
Fajar JK, Heriansyah T, Rohman MS. The predictors of no-reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: a meta-analysis. Indian Heart J. 2018;70(Suppl 3):S406-18.
Zhang D, Song X, Lv S, et al. Predicting coronary no-reflow in patients with acute ST-segment elevation myocardial infarction using Bayesian approaches. Coron Artery Dis. 2014;25: 582-8.
Avci E, Yildirim T, Aydin G, et al. Combining clinical predictors to better predict for the no-reflow phenomenon. Eur Rev Med Pharmacol Sci. 2018;22:4987-94.
Wang JW, Chen YD, Wang CH, et al. Development and validation of a clinical risk score predicting the no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Cardiology. 2013;124:153-60.
Dogan NB, Ozpelit E, Akdeniz S, et al. Simple clinical risk score for no-reflow prediction in patients undergoing primary percutaneous coronary intervention with acute STEMI. Pak J Med Sci. 2015;31:576-81.
Gibson CM, de Lemos JA, Murphy SA, et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001;103:2550-4.
Group TS. The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985;312:932-6.
Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101:125-30.
Jorapur V, Steigen TK, Buller CE, et al. Distribution and determinants of myocardial perfusion grade following late mechanical recanalization of occluded infarct-related arteries postmyocardial infarction: a report from the occluded artery trial. Catheter Cardiovasc Interv. 2008;72:783-9.
Reffelmann T, Kloner RA. The "no-reflow" phenomenon: basic science and clinical correlates. Heart. 2002;87:162-8.
Shi J, Jin H, Ou S. Clinical and angiographic features for predicting no-reflow phenomenon in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Shanghai Med J. 2010;33:430-3.
Soukoulis V, Boden WE, Smith SC Jr, et al. Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon. Circ Res. 2014;114:1944-58.
Zhao JL, Yang YJ, Zhang YH, et al. Chronic pretreatment of ACEI reduces no-reflow in patients with acute myocardial infarction treated with primary angioplasty. Clin Cardiol. 2007;30:130-4.
Hu T, Wang HC, Wang RT, et al. Effect of chronic pretreatment of angiotensin converting receptor blocker on no-reflow phenomenon in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Cardiovasc Ther. 2013;31:e7-11.
Albertal M, Cura F, Escudero AG, et al. Relationship between collateral circulation and successful myocardial reperfusion in acute myocardial infarction: a subanalysis of the PREMIAR trial. Angiology. 2008;59:587-92.
Desch S, Eitel I, Schmitt J, et al. Effect of coronary collaterals on microvascular obstruction as assessed by magnetic resonance imaging in patients with acute ST-elevation myocardial infarction treated by primary coronary intervention. Am J Cardiol. 2009;104:1204-9.
Galiuto L, Garramone B, Burzotta F, et al. Thrombus aspiration reduces microvascular obstruction after primary coronary intervention: a myocardial contrast echocardiography substudy of the REMEDIA Trial. J Am Coll Cardiol. 2006;48:1355-60.
Sardella G, Mancone M, Bucciarelli-Ducci C, et al. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial. J Am Coll Cardiol. 2009;53:309-15.
Amabile N, Jacquier A, Gaudart J, et al. Value of a new multiparametric score for prediction of microvascular obstruction lesions in ST-segment elevation myocardial infarction revascularized by percutaneous coronary intervention. Arch Cardiovasc Dis. 2010;103:512-21.
Gungor B, Alper AT, Ozcan KS, et al. Presence of sigma shaped right coronary artery is an indicator of poor prognosis in patients with inferior myocardial infarction treated with primary percutaneous coronary intervention. Catheter Cardiovasc Interv. 2014;84:965-72.
Ayhan E, Isik T, Ghannadian B, et al. The relationship between culprit artery and the clinical outcomes in patients undergoing primary percutaneous coronary intervention for inferior wall ST segment elevation myocardial infarction. Minerva Cardioangiol. 2016;64:367-74.
Stranders I, Diamant M, van Gelder RE, et al. Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch Intern Med. 2004;164:982-8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Asad Ullah Khan, Fazal Akbar , Shafi Ullah, Hasan Zeb
This work is licensed under a Creative Commons Attribution 4.0 International License.
